© 2021 © 2020 Genprex Inc. All Rights Reserved.
Inventor of the Company’s licensed diabetes gene therapy technology to provide leadership, strategy for diabetes program
New branding will support upcoming combination clinical trials, including the Company’s trial combining REQORSA™ immunogene therapy drug with AstraZeneca’s Tagrisso®, which received FDA Fast Track Designation earlier in 2020
Approval of new name marks important branding milestone and aligns with the program’s overall progress
Mr. Chapdelaine’s promotion follows the Company’s achievement of key manufacturing milestones to support upcoming clinical trials
Genprex’s President and Chief Executive Officer, Rodney Varner, will be delivering the company’s corporate presentation followed by a Q&A session with participants.
The 2020 Cell and Gene Meeting on the Mesa will be delivered in a virtual format over the course of five days where attendees will be able to watch company presentations on-demand, in addition to two live-streaming panels each day.
Gallagher’s appointment demonstrates the Company’s commitment to building a world-class intellectual property portfolio
Dr. Gannon will oversee and manage regulatory matters for the Company’s upcoming clinical trials, including its lead drug candidate in combination with Tagrisso® for which Fast Track Designation was received earlier this year.
Rodney Varner, Chairman and Chief Executive Officer of Genprex, will present virtually to an online audience on September 1, 2020 at 1:20 p.m. ET.
Company to provide update on its lead drug candidate, GPX-001 for non-small cell lung cancer, and its preclinical diabetes gene therapy candidate that may have the potential to cure Type 1 and Type 2 diabetes